All In Biotech

NDA 016320 · Kanchan Hlthcare

Myambutol

Ethambutol Hydrochloride · Oral

NovelPriority review

Last checked: Nov 20, 2026Latest source record: Feb 22, 2013 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1967

Nov 6, 1967

Approved uses

1

Original approval plus efficacy supplements

Registered trials

180

52 Phase 3, 27 recruiting

FAERS reports

2,718

2,227 serious, 334 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect May 5, 2026.

INDICATIONS ETHAMBUTOL HCl is indicated for the treatment of pulmonary tuberculosis. It should not be used as the sole antituberculous drug, but should be used in conjunction with at least one other antituberculous drug. Selection of the companion drug should be based on clinical experience, considerations of comparative safety, and appropriate in vitro susceptibility studies. In patients who have not received previous antituberculous therapy, ie, initial treatment, the most frequently used regimens have been the following: ETHAMBUTOL HCl plus isoniazidETHAMBUTOL HCl plus isoniazid plus streptomycin. In patients who have received previous antituberculous therapy, mycobacterial resistance to other drugs used in initial therapy is frequent. Consequently, in such retreatment patients, ETHAMBUTOL HCl should be combined with at least one of the second line drugs not previously administered to the patient and to which bacterial susceptibility has been indicated by appropriate in vitro studies. Antituberculous drugs used with ETHAMBUTOL HCl have included cycloserine, ethionamide, pyrazinamide, viomycin and other drugs. Isoniazid, aminosalicylic acid, and streptomycin have also been used in multiple drug regimens. Alternating drug regimens have also been utilized.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Nov 6, 1967 Original approval · Type 1 - New Molecular Entity · priority review
4 products under this application
  • MYAMBUTOL · ETHAMBUTOL HYDROCHLORIDE 200MG · TABLET, ORAL · Discontinued
  • MYAMBUTOL · ETHAMBUTOL HYDROCHLORIDE 400MG · TABLET, ORAL · Prescription · TE AB
  • MYAMBUTOL · ETHAMBUTOL HYDROCHLORIDE 100MG · TABLET, ORAL · Prescription · TE AB
  • MYAMBUTOL · ETHAMBUTOL HYDROCHLORIDE 500MG · TABLET, ORAL · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Ethambutol" as an intervention, any sponsor and status, largest first.

All 180 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • product use in unapproved indication215
  • pyrexia168
  • nausea134
  • vomiting126
  • drug interaction116
  • drug intolerance106
  • cough95
  • off label use95
  • dyspnoea93
  • diarrhoea89
  • immune reconstitution syndrome86
  • mycobacterium avium complex infection84

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200410
200512
200659
2007161
2008117
200976
2010162
2011196
2012198
201325
201433
201516
201616
201739
201850
201960
202081
202180
2022205
2023320
2024293
2025317
2026192

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 474 on PubMed

Sponsor: Kanchan Hlthcare

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.